Patients with hematological disorders are often thrombocytopenic due to the pathology of their disease and/or treatment. Platelet transfusions, used both therapeutically and prophylactically, only reduce clinically significant bleeding episodes from 50% to 43% of patients, so other treatments are often needed. In 2016 the Cochrane Library published a review of tranexamic acid (TXA) and another lysine analog—epsilon aminocaproic acid—for the…